Citations

Ansari, AS, Hussain M, Khan SR, Alam I, Lohiya NK. Pre-clinical evaluation for functional reversal with DMSO and NAHCO 3 following long-term contraception with RISUG in rats. Fertility and Sterility, 2012;98:3(S193-S193).

Chaki S.P., Das H.C., Misro M.M. A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG. Medline 2003;67:1(73-8).

Guha SK, Singh G, Anand S, Ansari S, Kumar S, Koul V. Phase I clinical trial of an injectable contraceptive for the male. Contraception 1993;48(4): 367-75.

Guha SK, Singh G, Ansari S, Kumar S, Srivastava A, Koul V, et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 1997;56:245-50.

Lohiya NK, Manivannan B, Mishra PK. Repeated vas occlusion and non-invasive reversal with styrene maleic anhydride for male contraception in langur monkeys. Int J Androl 2000;23:36-42.

Lohiya NK, Suthar R, Khandelwal A, Goyal S, Ansari AS, Manivannan B. Sperm characteristics and teratology in rats following vas deferens occlusion with RISUG and its reversal. Consumer Health Complete 2010;20.

Jha RK, Jha PK, Guha SK. Smart RISUG: a potential new contraceptive and its magnetic field-mediated sperm interaction. Int J Nanomedicine. 2009;4:55–64.